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ABSTRACTS
Gregory L. Moneta, MD, Abstracts Section EditorDescending Thoracic Aortic Aneurysm Repair: 12-year Experience
Using Distal Aortic Perfusion and Cerebrospinal Fluid Drainage
Estrera AL, Miller CC III, Chen EP, et al. Ann Thorac Surg 2005;80:
1290-6.
Conclusion: There is a low incidence of neurologic morbidity and a
relatively low mortality rate following descending thoracic aortic aneurysm
repair when distal aortic perfusion and cerebrospinal fluid drainage are
routinely utilized.
Summary: The authors sought to document their rate of neurologic
deficit andmortality following thoracic aneurysm repair with routine utilization
of distal aortic perfusion and cerebrospinal fluid drainage. There were 355
descending thoracic aortic aneurysms repaired at the author’s institution be-
tween February 1991 and September 2004. Twenty nine patients were ex-
cluded from analysis because of involvement of the aortic arch and 26 patients
with rupturewere also excluded. Therewere therefore 300 patients analyzed for
outcomes. Of these, 198 (66%) were men and 102 (35%) were women. Mean
age was 67 years. A combination of distal aortic perfusion and cerebrospinal
fluid drainage was utilized in 238 patients. There were 62 patients who under-
went simple cross-clamp without utilization of distal aortic perfusion or CSF
drainage.
There was a 2.3% incidence of neurologic deficit in this series (7 of 300
patients). The rate of neurologic deficits in the patients treated with cere-
brospinal fluid drainage and distal aortic perfusion was 1.3% (3 of 238
patients). The rate of neurologic deficit in patients not treated with cerebro-
spinal fluid drainage and distal aortic perfusion was 6.5% (4 of 62 patients; P
0.02). Neurologic deficits in both groups were only seen when the aneurysm
involved the entire descending thoracic aorta. Predictors of neurologic
deficit included use of cerebrospinal fluid drainage and distal aortic perfusion
(odds ratio [OR] 0.19; P  0.02), previous repaired abdominal aortic
aneurysm (OR, 7.0; P  0.005) and aneurysm that involved the entire
descending thoracic aorta (OR 13.73; P  0.02) and a history of cerebro-
vascular disease (OR 4.7; P 0.03). Thirty-day operative mortality was 8%.
Predictors of 30 daymortality were preoperative renal dysfunction (OR, 4.6;
P  0.01) and female sex (OR, 2.9; P  0.03).
Comment:This paper fromDr. Safi’s group inHouston indicates what
is possible to achieve with open thoracic aneurysm repair. I doubt this
volume of patients and this level of expertise is present in many institutions.
Because of this, papers such as this cannot really be used to justify or not
justify endovascular techniques of thoracic aneurysm repair. However, with
data such as this it would seem silly not to provide, when possible, CSF
drainage and distal aortic perfusion in patients undergoing open descending
thoracic aortic aneurysm repair.
MRI vs Helical CT for Endoleak Detection After Endovascular Aneu-
rysm Repair
Pitton NB, Schweitzer H, Herber S, et al. Am J Radiol 2005;185:1275-81.
Conclusion:MRI is far superior to biphasic CT scans for detection of
endoleaks following endovascular aneurysm repair.
Summary: There were 99 patients treated with Nitinol based stent
grafts between 1998-2003 at the author’s institution. Of these 47 were
excluded from analysis because they had follow up at another institution or
did not agree to undergo both CT and MRI imaging in follow up or had
claustrophobia or contrast allergy or poor renal function. Fifty-two patients
therefore had follow up data sets that included MRI and contrast enhanced
biphasic CT scans performed within 48 hours after stent graft placement and
at 3, 6, and 12 months and yearly thereafter. Endoleaks were categorized as
the percent of maximum cross sectional aneurysm area (3%, 3%  10%,
10%  30%, or 30%).
There were 252 data sets available for analysis and 141 showed evi-
dence of endoleak. Incidence of Types 1, 2, 3 and complex endoleak were
3.2%, 40.1%, 8.7%, and 4.0%, respectively. Sensitivities for endoleak detec-
tion forMRI, biphasic CT, uniphasic arterial CT, and uniphasic late CTwere
92.9%, 44.0%, 34.8%, and 38.3%, respectively. Corresponding negative
predictive values were 91.7%, 58.4%, 54.7%, and 56.1%. Overall accuracies
for MRI, biphasic CT, uniphasic arterial CT, and uniphasic late CT, were
95.2%, 58.3%, 55.6%, and 57.1%, respectively.
Comment: The data clearly implied that endoleak rates after endovas-
cular aneurysm repair are dependent upon the imaging modality utilized to
detect the endoleak. MRI appears to detect more endoleaks than CT. It is
interesting to speculate whether unexplained endotension after endovascu-
lar aneurysm repair essentially reflects undetected endoleak. Perhaps unex-
plained endotension after endovascular aneurysm repair would be explainedfar more often if MRI rather than CT was used routinely in the evaluation of
endoleaks following endovascular aortic aneurysm repair.
Trends in Serum Lipids and Lipoproteins of Adults 1960-2002
Carroll MD, Lacher DA, Sorlie PD, et al. JAMA 2005;294:1773-81.
Conclusion: Total cholesterol and LDL cholesterol levels show
continued decline from 1960-2002 with attainment of the target value of
no more than 17% of US adult population of having a total cholesterol
level 240 mg/dl.
Summary: Both total and low density lipoprotein (LDL) cholesterol
levels have been followed by the National Health and Nutrition Examina-
tion Surveys (NHANES) from 1960-2002. Overall both total and LDL
cholesterol levels have tended to decrease. This study focused on changes in
LDL and total cholesterol levels since the previous NHANES survey from
1988-1994. Blood lipid measurements were examined in 5 cross-sectional
surveys in the US population during the periods 1960-1962, 1971-1974,
1976-1980, 1988-1994, 1999-2002. Mean serum total cholesterol, LDL
cholesterol, high density lipoprotein (HDL) cholesterol and mean serum
triglyceride levels and the percentage of adults with a total serum choles-
terol 240 mg/dl were determined. There were from 6,000 in 1998 to
15,019 adults examined in the 5 district cross-sectional surveys.
Between 1988-1994 and 1999-2002 total cholesterol level of 20 years
or older adults decreased from 206mg/dl to 203mg/dl (P 0.009). LDL
cholesterol levels decreased from 129 mg/dl to 123 mg/dl (P  0.001).
Men who are 60 years of age had more significant decreases than
women 50 years of age. Overall, the percentage of adults with a total
cholesterol level 240 mg/dl decreased from 20% during the period of
1988-1984 to 17% during the period of 1999-2002 (P  0.001). Mean
HDL levels did not change and there was a nonsignificant increase in mean
serum triglycerides (P  0.06).
Comment: The data indicate continued and sustained progress in
reducing cholesterol levels in the US population. Now only 17% of the US
adult population has a total cholesterol level 240 mg/dl. Clearly there is still
room for improvement and further analyses targeting the ability to reduce
cholesterol levels in patients particularly at high risk for coronary disease and
other forms of vascular disease is required.
Secondary Prevention of Macro Vascular Events in Patients With Type
II Diabetes in the PROactive Study (PROspective Pioglitazone Clinical
Trial and Macro Vascular Events): A Randomised Controlled Trial
Dormandy JA, Charbonnel B, Eckland DJA, et al. Lancet 2005;366:1279-89.
Conclusion: In patients with Type II diabetes felt to be at high risk for
macro vascular events, Pioglitazone reduces the combination of all cause
mortality, non fatal myocardial infarction, and stroke.
Summary: This study sought to evaluate the effects of an antagonist of
peroxisome proliferator-activated receptor gamma for its ability to reduce
macro vascular complications in patients with Type II diabetes. This was a
prospective, randomized control trial involving 5,238 patients with Type II
diabetes and who had evidence of macro vascular disease. Patients were
recruited from both hospitals and primary care practices. Patients were
divided into two groups with one group treated with a titrated dose of
pioglitazone from 15 mgs to 45 mgs (n  2,605) with the second group
being a placebo control (n 2,603) study.Medications in both groups were
taken in addition to glucose lowering drugs and other indicated medica-
tions. The primary end point in the study was a composite of all cause
mortality, non fatal myocardial infarction, stroke, acute coronary syndrome,
and endovascular or surgical intervention in the coronary or leg arteries, or
amputation above the ankle. An intention to treat analysis was utilized.
There were only two patients lost to followup in this study. Average
observation time was 34.5 months. In the pioglitazone group, 514 patients
had at least one event in the primary composite end point versus 572 patients
in the placebo group (hazard ratio 0.9, 95% CI, 0.8-1.02, P 0.095). With
regard to the combination of all cause morality, non fatal myocardial
infarction, and stroke, 301 patients in the Pioglitazone group and 358
patients in the placebo group achieved this end point (hazard ratio 0.84, 95%
CI, 0.72-0.98, P  0.027). There was no change in the safety profile of
Pioglitazone noted. During the course of the study, 6% of the patients in the
Pioglitazone group and 4% in the placebo group were admitted to the
hospital with heart failure. There was no difference in mortality rates from
heart failure between the two groups.Comment: Pioglitazone reduces levels of inflammatory markers such
as C-reactive protein. These effects are independent of its affect on glycemic
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revascularization or need for amputation. There is beginning to be accumu-
lated evidence that systemic markers of inflammation are perhaps more
important in predicting coronary events than events secondary to peripheral
vascular disease. If this proves to be true, then the results of this study would
make sense in that one of the primary effects of this drug is to lower markers
of systemic inflammation.
Increased Platelet Count and Leukocyte-Platelet Complex Formation
in Acute Symptomatic Compared With Asymptomatic Severe Carotid
Stenosis
McCabe DJH, Harrison P, Mackie IJ, et al. Journal Neurology, Neurosur-
gery, Psychiatry 2005;76:1249-54.
Conclusion: The mechanism of symptomatic carotid stenosis predis-
posing to stroke may in part be related to increased platelet count and
leukocyte-platelet complex formation.
Summary: The authors sought to determine why risk of stroke is
significantly higher in patients with recently symptomatic carotid stenosis
versus those with asymptomatic carotid stenosis. They hypothesized that
excess platelet activation may contribute to this difference. Patients were
tested with whole blood flow cytometry to measure platelet surface expres-
sion of CD62P, CD63, and PAC1 binding and percentage of leukocyte
platelet complexes. Three groups of patients were evaluated. Those who had
acute symptoms in the previous 0-21 days (n  19), convalescent patients
who had symptoms from 79-365 days in the past (n 16), and patients with
asymptomatic carotid stenosis (n  16). Most patients were on aspirin,
although alternative anti-thrombotic therapies were used more often in the
patients with symptomatic carotid stenosis.
In patients with acute and convalescent symptomatic carotid stenosis,
the mean platelet count was higher than in patients with asymptomatic
carotid stenosis. There were no differences between CD62P, CD63, or
PAC1 binding between the three groups. Patients with acute symptomatic
carotid stenosis had higher median percentages of neutrophil-platelet,
monocyte-platelet, and lymphocyte-platelet complexes (p, 0.004, 0.046,
and 0.02 respectively). In patients on only aspirin therapy, neutrophil
platelet and monocyte platelet complexes were higher in those with acute
symptomatic plaques than in patients with asymptomatic plaques (P 
0.03). In patients with convalescent symptomatic carotid stenosis, median
percentages of leukocyte platelet complexes in the symptomatic group were
similar to those found in the asymptomatic group.
Comment: The severity of carotid stenosis appears to be reasonably
well correlated with symptoms in symptomatic patients and perhaps mod-
erately well correlated in asymptomatic patients. Nevertheless, most patients
with even severe carotid stenosis do not have strokes. Much research has
focused on the plaque as a discerning factor for risk of stroke in patients with
carotid stenosis. Research such as this presented here is also highly interest-
ing in that it suggests the risk of stroke is going to be effected not only by
stenosis and plaque composition, but also by blood rheology.
Association of a Functional Polymorphism in the Clopidogrel Target
Receptor Gene P2Y12 and the Risk for Ischemic Cerebrovascular
Events in Patients With Peripheral Arterial Disease
Ziegler S, Schillinger M, Funk M, et al. Stroke 2005;36:1394-9.
Conclusion: There is a variable response to Clopidogrel in patients
with peripheral arterial disease (PAD). This may lead to an increase in
cerebrovascular events.
Summary: Clopidogrel is an antiplatelet agent with considerable vari-
ability in antiplatelet affects. Clopidogrel resistance has been shown to be
associated with recurrent cardiovascular events in patients with acute coro-
nary syndromes. The authors assessed the effect of gene sequence variations
in P2Y12 with occurrence of neurologic adverse events in patients with
symptomatic PAD who were treated with clopidogrel. Patients who had
symptomatic PAD as manifested by intermittent claudication, critical limb
ischemia, or a history of surgical or endovascular lower limb revasculariza-
tion were eligible for the study. There were 137 patients who were under-
going antiplatelet therapy with clopidogrel and 336 who were treated with
aspirin. These patients were followed for occurrence of neurologic events
(ischemic stroke and/or carotid revascularization). Polymerase chain reac-
tion was used to determine the prevalence of 2 polymorphisms of the P2Y12
gene, 34CT and 52GT.
Mutated, heterozygous and wild type alleles for the 34 CT polymor-
phism were 9% (n  40), 44% (n  210), and 47% (n  223). Genotype
frequencies for the mutated, heterozygous and wild type alleles for the
52GT polymorphism were 4% (n  17), 27% (n  127), and 70% (n 
329). Median followup was 21 months. Eight percent of the patients had a
neurologic event during followup. Patients treated with aspirin showed no
association between neurologic events and either the 34CT or 52GT
polymorphisms. However, clopidogrel patients with at least one 34T allele
had a 4.02 times increased risk for neurologic events compared with carriers
of only 34C alleles (95% confidence interval, 1.08 to 14.9).Comment: Like with aspirin, there appears to be a significant inter-
individual variability in the antiplatelet effect of clopidogrel. This study
suggests identification of the 34CT polymorphismmay serve as a predictor
of the efficacy of clopidogrel to prevent neurologic events in patients with
PAD. Patients with neurologic events on antiplatelet therapy should prob-
ably be assessed for either aspirin or clopidogrel resistance, and their anti-
platelet agent adjusted accordingly.
Statins are Associated with Better Outcomes After Carotid Endarter-
ectomy in Symptomatic Patients
Kennedy J, Kuan H, Buchan AM, et al. Stroke 2005;36:2073-6.
Conclusion: Statin therapy appears to have a protective effect in
symptomatic patients undergoing carotid endarterectomy.
Summary: Pleiotropic effects of statins are widely appreciated. Statins
are associated with a reduction in mortality in non cardiac surgery. This
study determined the effect of statin use at the time of hospital admission in
patients undergoing carotid endarterectomy. The authors sought to deter-
mine whether statin use at the time of hospital admission in patients
undergoing carotid endarterectomy was associated with a reduction of
in-hospital adverse outcomes. All carotid endarterectomy cases were identi-
fied in four western Canadian provinces from January 2000 to December
2001. Charts were abstracted for data describing patient characteristics,
surgical indication for endarterectomy, statin treatment, and in-hospital
outcomes with respect to death, ischemic stroke, as well as cardiac outcomes.
There were 3,360 patients included in the data base. Logistic regression
analysis was used to compare outcomes of patients on statins versus those not
on statins and to account for differences in patient characteristics. Propensity
score analysis was used to account for factors that may influence patient
treatment with statins.
At the time of hospital admission, 815 of 2,031 symptomatic patients
and 665 of 1,252 asymptomatic patients were on a statin medication.
Symptomatic patients on statins had reduced in-hospital mortality and
in-hospital ischemic stroke and death rates. There was no difference in
in-hospital cardiac outcomes. (Adjusted odd ratios 0.25 {CI, 0.07 to 0.90},
0.55 {CI, 0.32 to 0.95}, 0.87 {CI, 0.49 to 1.54}, respectively). Improve-
ment in outcome of symptomatic patients was robust when tested with
propensity score analysis. The association between outcomes and statin use
was not seen in asymptomatic patients.
Comment:The study adds to the growing impression that statins improve
perioperative outcomes in patients undergoing vascular surgery. The lack of
effect of statins in the asymptomatic patients undergoing carotid endarterec-
tomy may be the result of an inability to detect the statin effect due to the low
frequency of adverse events in the asymptomatic patients. Since this was not a
randomized study, statins, however, may just be serving as a marker of overall
better perioperative care. Results of this observational study and others like it
will need to be confirmed in large multi-center randomized trials specifically
addressing perioperative use of statins to improve operative outcomes.
Relationship Between HbA1c Level and Peripheral Arterial Disease
Munter P, Wildman RP, Reynolds K, et al. Diabetes Care 2005;28:1981-7.
Conclusion: There is an association between higher levels of hemoglo-
bin A1c and peripheral arterial disease, even in patients without diabetes.
Summary: Glucose control is felt to be important in the development
of peripheral arterial disease (PAD) in patients with diabetes. Glucose
control may also be important in the development of PAD in patients
without diabetes. The authors sought to evaluate hemoglobin A1c levels in
patients with and without diabetes and to compare these levels with preva-
lence of PAD.
This was a cross sectional study utilizing 4,526 participants in the
National Health and Nutrition Examination Survey, 1999-2002. Partici-
pants were all40 years of age. PAD was defined as the presence of an ankle
brachial index (ABI) 0.9 (n  327).
In patients without diabetes, age standardized prevalence of PAD was
3.1%, 4.8%, 4.7%, and 6.4% for subjects with a hemoglobin A1c 5.3%,
5.3-5.4%, 5.5-5.6%, and 5.7-6.0%, respectively (p-trend less than 0.001). In
patients with diabetes, peripheral arterial disease prevalence was 7.5% and
8.8% with respect to hemoglobin A1c levels 7% and 7%. Using multi-
variable analysis adjustments in comparison with non diabetic subjects, with
hemoglobin A1c less than 5.3%, the odds ratio (95% confidence intervals) of
PAD for diabetic subjects with hemoglobin A1c 5.3-5.4%, 5.5-5.6%, and
5.7-6.0% was 1.41 (0.85-2.32), 1.39 (0.70-2.75), and 1.57 (1.02-2.47)
respectively. The odds ratios for peripheral arterial disease in diabetic partic-
ipants with hemoglobin A1c levels 7% versus those 7% were 2.33 (1.15-
4.70), and 2.74 (1.25-.02) respectively.
Comment: The data suggests higher levels of hemoglobin A1c in
patients without diabetes may serve as a marker for increased risk of sub-
clinical cardiovascular disease. It may be that it’s not so much diabetes but
glucose control that contributes to the risk of atherosclerosis. Perhaps
diabetes merely serves as one end of the spectrum of the adverse effects of
increased glucose levels on atherosclerosis.
